Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides for the use of a binding agent that binds to EpCAM and to CD137 in combination with a PD-1 axis binding antagonist in the treatment or prevention of a tumor or cancer, or to prevent progression of a tumor or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides for the use of a binding agent that binds to EpCAM and to CD137 in combination with a PD-1 axis binding antagonist in the treatment or prevention of a tumor or cancer, or to prevent progression of a tumor or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
8.
ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4
The present invention relates to a multispecific antibody comprising at least a FAPa binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
9.
MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION WITH ANTI PD-1 ANTIBODIES FOR TREATING CANCERS
The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to improved methods for reducing cytokine release syndrome following interruption of the epcoritamab dosing schedule for the treatment of CD20 B-cell expressing cancers.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides highly purified epcoritamab compositions, which comprise a bispecific antibody that binds CD3 and CD20. In the highly purified compositions, impurities, such as epcoritamab protein variants, process-related impurities and/or product-related impurities, have been minimized or removed. Methods of preparing the highly purified epcoritamab compositions are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to pharmaceutical compositions and unit dosage forms comprising antibodies binding to B7H4 and CD3. The invention further provides a use of the pharmaceutical compositions and unit dosage forms for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
The present disclosure provides highly purified epcoritamab compositions, which comprise a bispecific antibody that binds CD3 and CD20. In the highly purified compositions, impurities, such as epcoritamab protein variants, process-related impurities and/or product- related impurities, have been minimized or removed. Methods of preparing the highly purified epcoritamab compositions are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to improved methods for reducing cytokine release syndrome following interruption of the epcoritamab dosing schedule for the treatment of CD20 B-cell expressing cancers.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
17.
ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
18.
ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention provides dosing regimens of bispecific antibodies targeting both CD3 and CD20 when used in the treatment of lymphoma, such as B-cell Non-Hodgkin lymphoma (B-NHL).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention provides dosing regimens of bispecific antibodies targeting both CD3 and CD20 when used in the treatment of lymphoma, such as B-cell Non-Hodgkin lymphoma (B-NHL).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
21.
PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODIES BINDING TO CD30 AND CD3
The present invention relates to pharmaceutical compositions comprising multispecific antibodies capable of binding to CD3 and CD30. The present invention further provides use of the pharmaceutical compositions for therapeutic and diagnostic procedures, in particular for cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
22.
MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 FOR TREATING CANCER
The present invention relates to therapy using a binding agent that binds to human PD-L1 and to human CD137 to reduce or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
23.
MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN COMBINATION THERAPY FOR CANCER
The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological
preparations, especially antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for in vitro and in vivo scientific and industrial
research and development with regard to diseases; active
chemical ingredients for use in the manufacture of
pharmaceuticals. Pharmaceutical and veterinary preparations, including
pharmaceutical preparations based on antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for use with regard to diseases. Medical, scientific and biological research, especially
research into antibodies and bi- and multispecific
antibodies or fragments, including monovalent antibodies,
derivatives or conjugates of any of these and development of
pharmaceutical products based on antibodies and bi- and
multispecific antibodies or fragments, including monovalent
antibodies, derivatives or conjugates of any of these;
chemical analysis; computer programming, namely programming
of computers for the collection and processing of medical
data in medical scientific research, development and
therapy, including scientific research, development and
therapy with antibodies and bi- and multispecific antibodies
or fragments, including monovalent antibodies, derivatives
or conjugates of any of these. Patent exploitation and licensing of intellectual property
in the field of medicine.
Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
29.
COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS
The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
31.
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
32.
TROGOCYTOSIS-MEDIATED THERAPY USING CD38 ANTIBODIES
Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 35/02 - Antineoplastic agents specific for leukemia
The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
35.
HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
36.
MULTISPECIFIC ANTIBODY AGAINST CD40 AND CD137 IN COMBINATION THERAPY WITH ANTI-PD1 AB AND CHEMOTHERAPY
The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor which is an inhibitor of the PD-1/PD- L1 axis (in particular pembrolizumab) and chemotherapy to reduce or prevent progression of head and neck squamous cell carcinoma (HNSCC) or treat HNSCC.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
37.
MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY
The present disclosure relates generally to the field of multispecific binding agents for use in therapy, in particular for use in treating cancer, wherein the binding agents bind to human CD40 and to human CD137.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and pharmacological research services; clinical
trials; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials; all of the aforementioned within the area of
antibody therapeutics.
40.
BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING RICHTER'S SYNDROME
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to anti-CD38 antibodies comprising one or more mutations in the Fc region, and the use of such antibodies in the treatment of diseases in subjects, such as hematological malignancies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Described herein are proteins comprising an Fc region or the like, such as monoclonal, bispecific and multispecific antibodies, wherein the Fc region has been modified to eliminate or strongly reduce Fc-mediated effector functions, while at the same time allow for good developability, for therapeutic purposes and where such effector functions are undesired.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
43.
ANTI-DR5 FAMILY ANTIBODIES, BISPECIFIC OR MULTIVALENT ANTI-DR5 FAMILY ANTIBODIES AND METHODS OF USE THEREOF
Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals. Medical and pharmacological research services; clinical
trials; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and pharmacological research services; scientific research in the nature of conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; all of the aforementioned within the area of antibody therapeutics; none of the above in the field of data sharing, industrial automation, machine diagnostics, energy efficiency, and optimization of assets and of administrative processes in industry, healthcare, manufacturing and infrastructure
50.
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system and for the treatment of cancer, autoimmune diseases, and inflammatory disorders Medical and pharmacological research services; medical and scientific research services, namely conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
52.
MODIFIED IMMUNOGLOBULIN WITH AFFINITY FOR FcGAMMARIIb AND METHOD OF USE THEREOF
MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED (Australia)
GENMAB A/S (Denmark)
Inventor
Hogarth, Phillip Mark
Wines, Bruce David
Trist, Halina Mary
Esparon, Sandra Elizabeth
Chenoweth, Alicia Michelle
Abstract
Immunotherapeutic proteins comprising at least one heavy chain polypeptide derived from an IgG2 antibody are disclosed, wherein the heavy chain polypeptide comprises at least constant heavy domains 2 and 3 (CH2 and CH3) and the lower hinge, and the sequence of the lower hinge comprises a mutation enabling the immunotherapeutic protein to bind to and/or activate FcγRIIb. The immunotherapeutic protein is suitable for use in methods of treating diseases or conditions wherein, for example, the activation of FcγRIIb (ie for recruitment of the inhibitory functions of FcγRIIb) is beneficial, such as allergic diseases.
Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
55.
MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE
The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides combination therapy using a first binding agent comprising at least one binding region binding to CD27 in combination with a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137 to reduce progression or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
57.
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
58.
ANTIBODIES CAPABLE OF BINDING TO ROR2 AND BISPECIFIC ANTIBODIES BINDING TO ROR2 AND CD3
The present invention relates to antibodies binding to ROR2, including bispecific antibodies binding to ROR2 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
The present invention provides combination therapy using a binding agent comprises at least one binding region binding to CD27 in combination with a PD1/PD-L1 inhibitor to reduce progression or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
60.
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
The disclosure provides antibody-drug conjugates that bind to tissue factor (TF) (e.g, tisotumab vedotin) and its use in methods of treating cancer, such as head and neck squamous cell carcinoma or a gynecological cancer, including in combination with a radiation therapy. The disclosure also provides antibody-drug conjugates that bind to TF for use in combination with an additional chemotherapeutic, such as a platinum-based agent (e.g., carboplatin or cisplatin), including in combination with a radiation therapy, for treating cancer.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
65.
AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are methods of clinical treatment of chromic lymphoblastic leukemia (CLL) inhuman subjects using a bispecific-antibody which binds to CD3 and CD20.
Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of car regimen of gemcitabine and oxaliplatin (GemOx).
The present invention relates to combination therapy within the field of oncology; in particular to combination therapy with vaccines and binding agents binding to CD3 and to a target antigen on tumor cells.
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological preparations, namely, antibodies and bi- and multispecific antibodies in the nature of monoclonal antibodies for in vitro and in vivo scientific research and development use with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, autoimmune diseases, and inflammatory disorders Pharmaceutical and veterinary preparations, including pharmaceutical preparations based on antibodies for the treatment of cancer, autoimmune diseases, and inflammatory disorders Medical, scientific and biological research, namely, medical and scientific research into antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; computer programming, namely, programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, including scientific research, development and therapy with antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these Legal services related to the exploitation of patents and licensing of intellectual property in the field of medicine patents
72.
A COMPOSITION OF ANTI-DR5 ANTIBODIES AND AN IMMUNOMODULATORY IMIDE DRUG FOR USE IN TREATING MULTIPLE MYELOMA
The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide dmg. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention provides a binding agent that binds to EpCAM and to CD 137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention provides pharmaceutical formulations comprising antibodies binding to CD38 and to the use of said formulations in the treatment of cancer and other indications.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
76.
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and pharmacological research services; clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; all of the aforementioned within the area of antibody therapeutics.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals. Medical and pharmacological research services; Clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
80.
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
82.
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Provision of consumer information in the field of patient reimbursement and medical benefit support; Business administrative services for medical referrals in connection to patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Financial administration of patient reimbursement and patient financial assistance programs, namely reimbursement payment processing in the field of pharmaceutical and medical claims; Charitable services, namely, providing financial support to disadvantaged patients for the purpose of reimbursing medical and pharmaceutical expenses; Providing counseling and consulting in the field of healthcare insurance benefits in connection with patient reimbursement and patient financial assistance programs; Providing information about healthcare insurance plans, patient financial assistance, and patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Educational services, namely, conducting educational programs regarding patient support programs and financial assistance for healthcare; Educational services, namely providing courses of instruction in the field of disease management and navigation through medical treatments; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Medical assistance, namely disease management programs; provision of health care information in connection to disease management and navigation through medical treatments; provision of medical information in connection with health conditions and treatment of these conditions; medical counseling for patients in connection with disease management; Consultancy in the field of the medical treatment of cancer, autoimmune diseases, and inflammatory disorders; providing information to patients and families of patients in the field of administering medication and choosing treatments; providing a website featuring information in the medical and health fields in connection to disease management and navigation through medical treatments; health care services, namely disease management programs; medical and pharmaceutical consultation in connection to disease management; medical services, namely, provision of medical information for supporting patients in relation to the reimbursement of medical expenses; Providing a web site featuring medical information for patients in relation to the reimbursement of medical expenses; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Providing personal support services for patients and families of patients in connection to disease management and navigation through medical treatments, namely, emotional counseling and emotional support; Providing personal support services for families of patients with life threatening disorders in connection to disease management and reimbursement of medical expenses, namely, companionship, help with medical forms, emotional counseling and emotional support; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Provision of consumer information in the field of patient reimbursement and medical benefit support; Business administrative services for medical referrals in connection to patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Financial administration of patient reimbursement and patient financial assistance programs, namely reimbursement payment processing in the field of pharmaceutical and medical claims; Charitable services, namely, providing financial support to disadvantaged patients for the purpose of reimbursing medical and pharmaceutical expenses; Providing counseling and consulting in the field of healthcare insurance benefits in connection with patient reimbursement and patient financial assistance programs; Providing information about healthcare insurance plans, patient financial assistance, and patient reimbursement programs; Healthcare insurance services, namely, insurance eligibility review and verification, consultation and information in connection with patient reimbursement and patient financial assistance programs; Providing a database featuring information and statistics about patient reimbursement and insurance coverage for pharmaceuticals and medical treatments; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Educational services, namely, conducting educational programs regarding patient support programs and financial assistance for healthcare; Educational services, namely providing courses of instruction in the field of disease management and navigation through medical treatments; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Medical assistance, namely disease management programs; provision of health care information in connection to disease management and navigation through medical treatments; provision of medical information in connection with health conditions and treatment of these conditions; medical counseling for patients in connection with disease management; Consultancy in the field of the medical treatment of cancer, autoimmune diseases, and inflammatory disorders; providing information to patients and families of patients in the field of administering medication and choosing treatments; providing a website featuring information in the medical and health fields in connection to disease management and navigation through medical treatments; health care services, namely disease management programs; medical and pharmaceutical consultation in connection to disease management; medical services, namely, provision of medical information for supporting patients in relation to the reimbursement of medical expenses; Providing a web site featuring medical information for patients in relation to the reimbursement of medical expenses; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Providing personal support services for patients and families of patients in connection to disease management and navigation through medical treatments, namely, emotional counseling and emotional support; Providing personal support services for families of patients with life threatening disorders in connection to disease management and reimbursement of medical expenses, namely, companionship, help with medical forms, emotional counseling and emotional support; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Provision of consumer information in the field of patient reimbursement and medical benefit support; Business administrative services for medical referrals in connection to patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Financial administration of patient reimbursement and patient financial assistance programs, namely reimbursement payment processing in the field of pharmaceutical and medical claims; Charitable services, namely, providing financial support to disadvantaged patients for the purpose of reimbursing medical and pharmaceutical expenses; Providing counseling and consulting in the field of healthcare insurance benefits in connection with patient reimbursement and patient financial assistance programs; Providing information about healthcare insurance plans, patient financial assistance, and patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Educational services, namely, conducting educational programs regarding patient support programs and financial assistance for healthcare; Educational services, namely providing courses of instruction in the field of disease management and navigation through medical treatments; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Medical assistance, namely disease management programs; provision of health care information in connection to disease management and navigation through medical treatments; provision of medical information in connection with health conditions and treatment of these conditions; medical counseling for patients in connection with disease management; Consultancy in the field of the medical treatment of cancer, autoimmune diseases, and inflammatory disorders; providing information to patients and families of patients in the field of administering medication and choosing treatments; providing a website featuring information in the medical and health fields in connection to disease management and navigation through medical treatments; health care services, namely disease management programs; medical and pharmaceutical consultation in connection to disease management; medical services, namely, provision of medical information for supporting patients in relation to the reimbursement of medical expenses; Providing a web site featuring medical information for patients in relation to the reimbursement of medical expenses; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Providing personal support services for patients and families of patients in connection to disease management and navigation through medical treatments, namely, emotional counseling and emotional support; Providing personal support services for families of patients with life threatening disorders in connection to disease management and reimbursement of medical expenses, namely, companionship, help with medical forms, emotional counseling and emotional support; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Provision of consumer information in the field of patient reimbursement and medical benefit support; Business administrative services for medical referrals in connection to patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Financial administration of patient reimbursement and patient financial assistance programs, namely reimbursement payment processing in the field of pharmaceutical and medical claims; Charitable services, namely, providing financial support to disadvantaged patients for the purpose of reimbursing medical and pharmaceutical expenses; Providing counseling and consulting in the field of healthcare insurance benefits in connection with patient reimbursement and patient financial assistance programs; Providing information about healthcare insurance plans, patient financial assistance, and patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Educational services, namely, conducting educational programs regarding patient support programs and financial assistance for healthcare; Educational services, namely providing courses of instruction in the field of disease management and navigation through medical treatments; providing online publications, namely non-downloadable brochures, written articles and guidebooks in the field of medical information and patient support in connection with patient reimbursement and patient financial assistance programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Medical assistance, namely disease management programs; provision of health care information in connection to disease management and navigation through medical treatments; provision of medical information in connection with health conditions and treatment of these conditions; medical counseling for patients in connection with disease management; Consultancy in the field of the medical treatment of cancer, autoimmune diseases, and inflammatory disorders; providing information to patients and families of patients in the field of administering medication and choosing treatments; providing a website featuring information in the medical and health fields in connection to disease management and navigation through medical treatments; health care services, namely disease management programs; medical and pharmaceutical consultation in connection to disease management; medical services, namely, provision of medical information for supporting patients in relation to the reimbursement of medical expenses; Providing a web site featuring medical information for patients in relation to the reimbursement of medical expenses; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Providing personal support services for patients and families of patients in connection to disease management and navigation through medical treatments, namely, emotional counseling and emotional support; Providing personal support services for families of patients with life threatening disorders in connection to disease management and reimbursement of medical expenses, namely, companionship, help with medical forms, emotional counseling and emotional support; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Provision of consumer information in the field of patient reimbursement and medical benefit support; Business administrative services for medical referrals; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Financial administration of patient reimbursement and patient financial assistance programs, namely reimbursement payment processing in the field of pharmaceutical and medical claims;
Charitable services, namely, providing financial support to disadvantaged patients for the purpose of reimbursing medical and pharmaceutical expenses; Providing counseling and consulting in the field of healthcare insurance benefits in connection with patient reimbursement and patient financial assistance programs; Providing information about healthcare insurance plans, patient financial assistance, and patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of
the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Educational services, namely, conducting educational programs regarding patient support programs and financial assistance for healthcare; Educational services, namely providing courses of instruction in the field of disease management and navigation through medical treatments; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth
beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Medical assistance, namely disease management programs; provision of health care information in connection to disease management and navigation through medical treatments; provision of medical information in connection with health conditions and treatment of these conditions; medical counseling for patients in connection with disease management; Consultancy in the field of the medical treatment of cancer, autoimmune diseases, and inflammatory disorders; providing information to patients and families of patients in the field of administering medication and choosing treatments; providing a website featuring information in the medical and health fields in connection to disease management and navigation through medical treatments; health care services, namely disease management programs; medical and pharmaceutical consultation in connection to disease management; medical services, namely, provision of medical information for supporting patients in relation to the reimbursement of medical expenses; Providing a web site featuring medical information for patients in relation to the reimbursement of medical expenses; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Providing personal support services for patients and families of patients in connection to disease management and navigation through medical treatments, namely, emotional counseling and emotional support; Providing personal support services for families of patients with life threatening disorders in connection to disease management and reimbursement of medical expenses, namely, companionship, help with medical forms, emotional counseling and emotional support; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Provision of consumer information in the field of patient reimbursement and medical benefit support; Business administrative services for medical referrals in connection to patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Financial administration of patient reimbursement and patient financial assistance programs, namely reimbursement payment processing in the field of pharmaceutical and medical claims; Charitable services, namely, providing financial support to disadvantaged patients for the purpose of reimbursing medical and pharmaceutical expenses; Providing counseling and consulting in the field of healthcare insurance benefits in connection with patient reimbursement and patient financial assistance programs; Providing information about healthcare insurance plans, patient financial assistance, and patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiarie Educational services, namely, conducting educational programs regarding patient support programs and financial assistance for healthcare; Educational services, namely providing courses of instruction in the field of disease management and navigation through medical treatments; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Medical assistance, namely disease management programs; provision of health care information in connection to disease management and navigation through medical treatments; provision of medical information in connection with health conditions and treatment of these conditions; medical counseling for patients in connection with disease management; Consultancy in the field of the medical treatment of cancer, autoimmune diseases, and inflammatory disorders; providing information to patients and families of patients in the field of administering medication and choosing treatments; providing a website featuring information in the medical and health fields in connection to disease management and navigation through medical treatments; health care services, namely disease management programs; medical and pharmaceutical consultation in connection to disease management; medical services, namely, provision of medical information for supporting patients in relation to the reimbursement of medical expenses; Providing a web site featuring medical information for patients in relation to the reimbursement of medical expenses; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries Providing personal support services for patients and families of patients in connection to disease management and navigation through medical treatments, namely, emotional counseling and emotional support; Providing personal support services for families of patients with life threatening disorders in connection to disease management and reimbursement of medical expenses, namely, companionship, help with medical forms, emotional counseling and emotional support; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological
preparations, especially antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for in vitro and in vivo scientific, research and
development use with regard to diseases; active chemical
ingredients for use in the manufacture of pharmaceuticals. Pharmaceutical and veterinary preparations, including
pharmaceutical preparations based on antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for use with regard to diseases. Medical, scientific and biological research, especially
research into antibodies and bi- and multispecific
antibodies or fragments, including monovalent antibodies,
derivatives or conjugates of any of these and development of
pharmaceutical products based on antibodies and bi- and
multispecific antibodies or fragments, including monovalent
antibodies, derivatives or conjugates of any of these;
chemical analysis; computer programming, namely programming
of computers for the collection and processing of medical
data in medical scientific research, development and
therapy, including scientific research, development and
therapy with antibodies and bi- and multispecific antibodies
or fragments, including monovalent antibodies, derivatives
or conjugates of any of these. Patent exploitation and licensing of intellectual property
in the field of medicine.
The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
95.
MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY
The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
96.
MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION WITH ANTI PD-1 ANTIBODIES FOR TREATING CANCERS
The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
